These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20521434)

  • 61. Aspirin for the primary prevention of cardiovascular disease: latest evidence.
    Capodanno D; Ingala S; Calderone D; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2019 Sep; 17(9):633-643. PubMed ID: 31382819
    [No Abstract]   [Full Text] [Related]  

  • 62. [Is the "polypill" in cardiovascular prevention an option].
    Flatz A; Renard D; von Elm E
    Praxis (Bern 1994); 2015 Mar; 104(6):305-6. PubMed ID: 25758972
    [No Abstract]   [Full Text] [Related]  

  • 63. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
    Wang TH; Bhatt DL; Fox KA; Steinhubl SR; Brennan DM; Hacke W; Mak KH; Pearson TA; Boden WE; Steg PG; Flather MD; Montalescot G; Topol EJ;
    Eur Heart J; 2007 Sep; 28(18):2200-7. PubMed ID: 17673448
    [TBL] [Abstract][Full Text] [Related]  

  • 64. PROCAM-, FRAMINGHAM-, SCORE- and SMART-risk score for predicting cardiovascular morbidity and mortality: a comment.
    Wiwanitkit V
    Vasa; 2011 Mar; 40(2):167; author reply 167-8. PubMed ID: 21591472
    [No Abstract]   [Full Text] [Related]  

  • 65. Statins and all-cause mortality in high-risk primary prevention: a second look at the results.
    Chodick G; Shalev V
    Arch Intern Med; 2010 Dec; 170(22):2041-2; author reply 2043-4. PubMed ID: 21149767
    [No Abstract]   [Full Text] [Related]  

  • 66. Does aspirin use prevent acute coronary syndrome in patients with pneumonia: multicenter prospective randomized trial.
    Oz F; Gul S; Kaya MG; Yazici M; Bulut I; Elitok A; Ersin G; Abakay O; Akkoyun CD; Oncul A; Cetinkaya E; Gibson MC; Oflaz H
    Coron Artery Dis; 2013 May; 24(3):231-7. PubMed ID: 23283029
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cardiovascular pharmacology core reviews: aspirin.
    Gaglia MA; Clavijo L
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):505-13. PubMed ID: 24057863
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials.
    Berger JS; Lala A; Krantz MJ; Baker GS; Hiatt WR
    Am Heart J; 2011 Jul; 162(1):115-24.e2. PubMed ID: 21742097
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The ASPRE pre-eclampsia trial: implications for basic research and clinical practice.
    Thilaganathan B
    Cardiovasc Res; 2018 Jul; 114(8):e60-e61. PubMed ID: 30052896
    [No Abstract]   [Full Text] [Related]  

  • 70. Aspirin for primary prevention: what's a clinician to do?
    Psotka MA; Fleischmann KE
    J Gen Intern Med; 2015 Feb; 30(2):147-9. PubMed ID: 25451988
    [No Abstract]   [Full Text] [Related]  

  • 71. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
    Palumbo A; Cavo M; Bringhen S; Zamagni E; Romano A; Patriarca F; Rossi D; Gentilini F; Crippa C; Galli M; Nozzoli C; Ria R; Marasca R; Montefusco V; Baldini L; Elice F; Callea V; Pulini S; Carella AM; Zambello R; Benevolo G; Magarotto V; Tacchetti P; Pescosta N; Cellini C; Polloni C; Evangelista A; Caravita T; Morabito F; Offidani M; Tosi P; Boccadoro M
    J Clin Oncol; 2011 Mar; 29(8):986-93. PubMed ID: 21282540
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Epidemiology and prevention of cardiovascular diseases].
    Jánosi A
    Orv Hetil; 2005 Apr; 146(15):683-8. PubMed ID: 15895792
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Aspirin for primary prevention of cardiovascular disease (revisited).
    Med Lett Drugs Ther; 2006 Jul; 48(1238):53. PubMed ID: 16841021
    [No Abstract]   [Full Text] [Related]  

  • 74. Comparison of efficacy of antiplatelet treatments for patients with claudication. A meta-analysis.
    Basili S; Raparelli V; Vestri A; Di Tanna GL; Violi F
    Thromb Haemost; 2010 Apr; 103(4):766-73. PubMed ID: 20174763
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Primary and secondary prevention of cardiovascular disease in diabetes with aspirin.
    Schnell O; Erbach M; Hummel M
    Diab Vasc Dis Res; 2012 Oct; 9(4):245-55. PubMed ID: 22508698
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The aspirin controversy in primary prevention.
    Raju NC; Eikelboom JW
    Curr Opin Cardiol; 2012 Sep; 27(5):499-507. PubMed ID: 22874127
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The role of the cardiologist in the primary prevention of cardiovascular disease with aspirin.
    Verheugt FW
    J Am Coll Cardiol; 2015 Jan; 65(2):122-4. PubMed ID: 25593052
    [No Abstract]   [Full Text] [Related]  

  • 78. Aspirin dosing for atherosclerotic cardiovascular disease: should we be more ADAPTABLE?
    Parker WAE; Storey RF
    Cardiovasc Res; 2021 Aug; 117(10):e123-e125. PubMed ID: 34370832
    [No Abstract]   [Full Text] [Related]  

  • 79. [I Brazilian Guidelines for cardiovascular prevention].
    Simão AF; Precoma DB; Andrade JP; Correa FH; Saraiva JF; Oliveira GM; Murro AL; Campos A; Alessi A; Avezum A; Achutti AC; Miguel AC; Sousa AC; Lotemberg AM; Lins AP; Falud AA; Brandão AA; Sanjuliani AF; Sbissa AS; Alencar FA; Herdy AH; Polanczyk CA; Lantieri CJ; Machado CA; Scherr C; Stoll C; Amodeo C; Araújo CG; Saraiva D; Moriguchi EH; Mesquita ET; Fonseca FA; Campos GP; Soares GP; Feitosa GS; Xavier HT; Castro I; Giuliano IC; Rivera IV; Guimaraes IC; Issa JS; Souza JR; Faria NJ; Cunha LB; Pellanda LC; Bortolotto LA; Bertolami MC; Miname MH; Gomes MA; Tambascia M; Malachias MV; Silva MA; Izar MC; Magalhães ME; Bacellar MS; Milani M; Wajngarten M; Ghorayeb N; Coelho OR; Villela PB; Jardim PC; Santos Filho RD; Stein R; Cassani RS; D'Avila RI; Ferreira RM; Barbosa RB; Povoa RM; Kaiser SE; Ismael SC; Carvalho T; Giraldez VZ; Coutinho W; Souza WK;
    Arq Bras Cardiol; 2013 Dec; 101(6 Suppl 2):1-63. PubMed ID: 24554026
    [No Abstract]   [Full Text] [Related]  

  • 80. Use of a Geographic Information System to create treatment groups for group-randomized community trials: The Minnesota Heart Health Program.
    Krzyzanowski B; Manson SM; Eder MM; Kne L; Oldenburg N; Peterson K; Hirsch AT; Luepker RV; Duval S
    Trials; 2019 Mar; 20(1):185. PubMed ID: 30922358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.